Drucker, Daniel J.

GLP-1 physiology informs the pharmacotherapy of obesity

Drucker, D. J. (2022) · Molecular Metabolism

Regulation of Appetite and ObesityPharmacology and Obesity Treatment

Cited by 510

Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons

Yamamoto, H., Lee, C. E., Marcus, J. N., Williams, T. D., Overton, J. M., Lopez, M. E., Hollenberg, A. N., Baggio, L., Saper, C. B., Drucker, D. J., et al. (2002) · Journal of Clinical Investigation

Neuropeptides and Animal PhysiologyHeart Rate Variability and Autonomic Control

Cited by 429

Discovery, characterization, and clinical development of the glucagon-like peptides

Drucker, D. J., Habener, J. F., & Holst, J. J. (2017) · Journal of Clinical Investigation

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 418

Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications

Drucker, D. J. (2020) · Endocrine Reviews

Diabetes Treatment and ManagementCOVID-19 Clinical Research Studies

Cited by 399

Gut microbiota confers host resistance to obesity by metabolizing dietary polyunsaturated fatty acids

Miyamoto, J., Igarashi, M., Watanabe, K., Karaki, S.-I., Mukouyama, H., Kishino, S., Li, X., Ichimura, A., Irie, J., Sugimoto, Y., et al. (2019) · Nature Communications

Gut microbiota and healthFatty Acid Research and Health

Cited by 392

Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity

Drucker, D. J. (2024) · Diabetes Care

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 383

Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure

Baggio, L. L., Huang, Q., Brown, T. J., & Drucker, D. J. (2004) · Gastroenterology

Regulation of Appetite and ObesityNeuropeptides and Animal Physiology

Cited by 372

Cardiovascular Actions of Incretin-Based Therapies

Ussher, J. R., & Drucker, D. J. (2014) · Circulation Research

Diabetes Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 358

GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic Male ApoE−/− Mice

Panjwani, N., Mulvihill, E. E., Longuet, C., Yusta, B., Campbell, J. E., Brown, T. J., Streutker, C., Holland, D., Cao, X., Baggio, L. L., et al. (2013) · Endocrinology

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 346

The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential

Fujita, H., Morii, T., Fujishima, H., Sato, T., Shimizu, T., Hosoba, M., Tsukiyama, K., Narita, T., Takahashi, T., Drucker, D. J., et al. (2014) · Kidney International

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 336

The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling

Zhang, Q., Delessa, C. T., Augustin, R., Bakhti, M., Colldén, G., Drucker, D. J., Feuchtinger, A., Caceres, C. G., Grandl, G., Harger, A., et al. (2021) · Cell Metabolism

Regulation of Appetite and ObesityDiabetes Treatment and Management

Cited by 322

Intestinal growth-promoting properties of glucagon-like peptide-2 in mice

Tsai, C. H., Hill, M., Asa, S. L., Brubaker, P. L., & Drucker, D. J. (1997) · American Journal of Physiology-Endocrinology and Metabolism

Diabetes Treatment and ManagementRegulation of Appetite and Obesity

Cited by 319

The Murine Glucagon-Like Peptide-1 Receptor Is Essential for Control of Bone Resorption

Yamada, C., Yamada, Y., Tsukiyama, K., Yamada, K., Udagawa, N., Takahashi, N., Tanaka, K., Drucker, D. J., Seino, Y., & Inagaki, N. (2008) · Endocrinology

Bone Metabolism and DiseasesBone health and osteoporosis research

Cited by 318

Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits

Drucker, D. J., Sherman, S. I., Gorelick, F. S., Bergenstal, R. M., Sherwin, R. S., & Buse, J. B. (2010) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 316

GLP-1 Receptor Expression Within the Human Heart

Baggio, L. L., Yusta, B., Mulvihill, E. E., Cao, X., Streutker, C. J., Butany, J., Cappola, T. P., Margulies, K. B., & Drucker, D. J. (2018) · Endocrinology

Diabetes Treatment and ManagementNeuropeptides and Animal Physiology

Cited by 312

Double Incretin Receptor Knockout (DIRKO) Mice Reveal an Essential Role for the Enteroinsular Axis in Transducing the Glucoregulatory Actions of DPP-IV Inhibitors

Hansotia, T., Baggio, L. L., Delmeire, D., Hinke, S. A., Yamada, Y., Tsukiyama, K., Seino, Y., Holst, J. J., Schuit, F., & Drucker, D. J. (2004) · Diabetes

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 309

Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation

Wong, C. K., McLean, B. A., Baggio, L. L., Koehler, J. A., Hammoud, R., Rittig, N., Yabut, J. M., Seeley, R. J., Brown, T. J., & Drucker, D. J. (2024) · Cell Metabolism

Diabetes Treatment and ManagementNeuropeptides and Animal Physiology

Cited by 304

Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease.

Baggio, L. L., & Drucker, D. J. (2021) · Molecular Metabolism

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 299

Glucagon-Like Peptide-1-Responsive Catecholamine Neurons in the Area Postrema Link Peripheral Glucagon-Like Peptide-1 with Central Autonomic Control Sites

Yamamoto, H., Kishi, T., Lee, C. E., Choi, B. J., Fang, H., Hollenberg, A. N., Drucker, D. J., & Elmquist, J. K. (2003) · The Journal of Neuroscience

Neuropeptides and Animal PhysiologyRegulation of Appetite and Obesity

Cited by 294

Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure

Hansotia, T., Maida, A., Flock, G., Yamada, Y., Tsukiyama, K., Seino, Y., & Drucker, D. J. (2007) · Journal of Clinical Investigation

Diabetes Treatment and ManagementRegulation of Appetite and Obesity

Cited by 290

Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation

McLean, B. A., Wong, C. K., Campbell, J. E., Hodson, D. J., Trapp, S., & Drucker, D. J. (2021) · Endocrine Reviews

Diabetes Treatment and ManagementRegulation of Appetite and Obesity

Cited by 289

Endothelial GLP-1 (Glucagon-Like Peptide-1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension

Helmstädter, J., Frenis, K., Filippou, K., Grill, A., Dib, M., Kalinovic, S., Pawelke, F., Kus, K., Kröller-Schön, S., Oelze, M., et al. (2020) · Arteriosclerosis, Thrombosis, and Vascular Biology

Diabetes Treatment and ManagementNitric Oxide and Endothelin Effects

Cited by 283

GLP-1R Agonists Modulate Enteric Immune Responses Through the Intestinal Intraepithelial Lymphocyte GLP-1R

Yusta, B., Baggio, L. L., Koehler, J., Holland, D., Cao, X., Pinnell, L. J., Johnson-Henry, K. C., Yeung, W., Surette, M. G., Bang, K. W. A., et al. (2015) · Diabetes

Diabetes Treatment and ManagementGut microbiota and health

Cited by 282

Glucagon-Like Peptide-1 and the Islet β-Cell: Augmentation of Cell Proliferation and Inhibition of Apoptosis

Drucker, D. J. (2003) · Endocrinology

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 274